PL2542576T3 - Sposoby badań przesiewowych przeciwciał - Google Patents
Sposoby badań przesiewowych przeciwciałInfo
- Publication number
- PL2542576T3 PL2542576T3 PL11751155.0T PL11751155T PL2542576T3 PL 2542576 T3 PL2542576 T3 PL 2542576T3 PL 11751155 T PL11751155 T PL 11751155T PL 2542576 T3 PL2542576 T3 PL 2542576T3
- Authority
- PL
- Poland
- Prior art keywords
- methods
- screening antibodies
- antibodies
- screening
- Prior art date
Links
- 238000000034 method Methods 0.000 title 1
- 238000012216 screening Methods 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
- G01N33/532—Production of labelled immunochemicals
- G01N33/533—Production of labelled immunochemicals with fluorescent label
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Analytical Chemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US30972510P | 2010-03-02 | 2010-03-02 | |
| US32343310P | 2010-04-13 | 2010-04-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2542576T3 true PL2542576T3 (pl) | 2016-10-31 |
Family
ID=44542524
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL11751155.0T PL2542576T3 (pl) | 2010-03-02 | 2011-02-28 | Sposoby badań przesiewowych przeciwciał |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US9725500B2 (pl) |
| EP (1) | EP2542576B1 (pl) |
| JP (5) | JP5797210B2 (pl) |
| CN (1) | CN102858798B (pl) |
| CA (1) | CA2788289C (pl) |
| DK (1) | DK2542576T3 (pl) |
| ES (1) | ES2581314T3 (pl) |
| PL (1) | PL2542576T3 (pl) |
| PT (1) | PT2542576T (pl) |
| WO (1) | WO2011109308A1 (pl) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10107782B2 (en) | 2008-01-25 | 2018-10-23 | ProteinSimple | Method to perform limited two dimensional separation of proteins and other biologicals |
| ES2581314T3 (es) * | 2010-03-02 | 2016-09-05 | Seattle Genetics, Inc. | Métodos de cribado de anticuerpos |
| US9717803B2 (en) | 2011-12-23 | 2017-08-01 | Innate Pharma | Enzymatic conjugation of polypeptides |
| US9804079B2 (en) | 2012-04-19 | 2017-10-31 | ProteinSimple | Dual wavelength isoelectric focusing for determining drug load in antibody drug conjugates |
| EP2872894B1 (en) | 2012-07-13 | 2019-04-17 | Innate Pharma | Screening of conjugated antibodies |
| EP2916872B1 (en) | 2012-11-09 | 2019-02-27 | Innate Pharma | Recognition tags for tgase-mediated conjugation |
| EP2968582B1 (en) * | 2013-03-15 | 2020-07-01 | Innate Pharma | Solid phase tgase-mediated conjugation of antibodies |
| GB2513405A (en) * | 2013-04-26 | 2014-10-29 | Adc Biotechnology Ltd | Method of synthesising ADCs using affinity resins |
| US10071169B2 (en) | 2013-06-20 | 2018-09-11 | Innate Pharma | Enzymatic conjugation of polypeptides |
| JP6744212B2 (ja) | 2013-06-21 | 2020-08-19 | イナート・ファルマ・ソシエテ・アノニムＩｎｎａｔｅ Ｐｈａｒｍａ Ｐｈａｒｍａ Ｓ．Ａ． | ポリペプチドの酵素的結合 |
| US9766206B2 (en) | 2013-09-27 | 2017-09-19 | ProteinSimple | Apparatus, systems, and methods for capillary electrophoresis |
| AU2014337555C1 (en) | 2013-10-15 | 2021-01-28 | Seagen Inc. | PEGylated drug-linkers for improved Ligand-Drug Conjugate pharmacokinetics |
| MX2017001022A (es) * | 2014-07-24 | 2017-12-20 | Genentech Inc | Metodos para conjugar un agente a un resto tiol en una proteina que contiene al menos un enlace trisulfuro. |
| GB201419185D0 (en) * | 2014-10-28 | 2014-12-10 | Adc Biotechnology Ltd | Method of synthesising ADCs using affinity resin |
| US11173213B2 (en) * | 2015-06-29 | 2021-11-16 | Daiichi Sankyo Company, Limited | Method for selectively manufacturing antibody-drug conjugate |
| KR102626498B1 (ko) | 2016-03-25 | 2024-01-19 | 씨젠 인크. | 페길화된 약물-링커 및 그의 중간체의 제조를 위한 공정 |
| WO2018175994A1 (en) | 2017-03-24 | 2018-09-27 | Seattle Genetics, Inc. | Process for the preparation of glucuronide drug-linkers and intermediates thereof |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1203164A (en) * | 1982-03-09 | 1986-04-15 | Thomas J. Mckearn | Antibody conjugates |
| US20020197694A1 (en) | 2001-06-20 | 2002-12-26 | Weiping Shao | Conjugates of reduced antibodies and biomolecules |
| EP1409478B1 (en) * | 2001-07-16 | 2006-03-29 | Janssen Pharmaceutica N.V. | Improved process for preparing benzimidazole-type compounds |
| US20090068178A1 (en) * | 2002-05-08 | 2009-03-12 | Genentech, Inc. | Compositions and Methods for the Treatment of Tumor of Hematopoietic Origin |
| US20030232386A1 (en) * | 2002-06-17 | 2003-12-18 | Shah Dinesh O. | Assay conjugate and uses thereof |
| JP4741838B2 (ja) * | 2002-07-31 | 2011-08-10 | シアトル ジェネティクス，インコーポレーテッド | 癌、自己免疫疾患または感染症を治療するための薬物結合体およびその使用 |
| US20040038331A1 (en) | 2002-08-23 | 2004-02-26 | Reddy M. Parameswara | Solid phase synthesis of biomolecule conjugates |
| CN104998273A (zh) * | 2003-11-06 | 2015-10-28 | 西雅图基因公司 | 能够与配体偶联的单甲基缬氨酸化合物 |
| ES2533695T3 (es) | 2004-03-02 | 2015-04-14 | Seattle Genetics, Inc. | Anticuerpos cargados parcialmente y métodos para su conjugación |
| CN109045307A (zh) * | 2004-06-01 | 2018-12-21 | 健泰科生物技术公司 | 抗体-药物偶联物和方法 |
| CA2567520A1 (en) | 2004-06-01 | 2005-12-15 | Genentech, Inc. | Maytansinoid-antibody conjugates |
| PT1912677E (pt) | 2005-06-20 | 2013-12-23 | Psma Dev Company L L C | Conjugados de anticorpos contra psma-fármaco |
| WO2007100385A2 (en) | 2005-10-31 | 2007-09-07 | Genentech, Inc. | Macrocyclic depsipeptide antibody-drug conjugates and methods |
| CA2656168A1 (en) * | 2006-06-22 | 2007-12-27 | Genentech, Inc. | Methods and compositions for targeting hepsin |
| MX2009003938A (es) * | 2006-10-27 | 2009-04-24 | Genentech Inc | Anticuerpos e inmunoconjugados y sus usos. |
| US20080233660A1 (en) | 2007-03-23 | 2008-09-25 | Mu Bioteknik Ab | Solid phase labeling method |
| PT2211904T (pt) * | 2007-10-19 | 2016-11-02 | Seattle Genetics Inc | Agentes de ligação a cd19 e seus usos |
| US8900589B2 (en) * | 2008-07-15 | 2014-12-02 | Genetech, Inc. | Anthracycline derivative conjugates, process for their preparation and their use as antitumor compounds |
| US9395370B2 (en) | 2009-07-08 | 2016-07-19 | Bio-Rad Laboratories, Inc. | Purification of monoclonal antibodies |
| ES2581314T3 (es) * | 2010-03-02 | 2016-09-05 | Seattle Genetics, Inc. | Métodos de cribado de anticuerpos |
-
2011
- 2011-02-28 ES ES11751155.0T patent/ES2581314T3/es active Active
- 2011-02-28 CA CA2788289A patent/CA2788289C/en active Active
- 2011-02-28 PL PL11751155.0T patent/PL2542576T3/pl unknown
- 2011-02-28 US US13/581,236 patent/US9725500B2/en not_active Expired - Fee Related
- 2011-02-28 PT PT117511550T patent/PT2542576T/pt unknown
- 2011-02-28 CN CN201180020718.1A patent/CN102858798B/zh active Active
- 2011-02-28 WO PCT/US2011/026534 patent/WO2011109308A1/en not_active Ceased
- 2011-02-28 JP JP2012556142A patent/JP5797210B2/ja active Active
- 2011-02-28 EP EP11751155.0A patent/EP2542576B1/en active Active
- 2011-02-28 DK DK11751155.0T patent/DK2542576T3/en active
-
2015
- 2015-08-18 JP JP2015161040A patent/JP5998261B2/ja active Active
-
2016
- 2016-08-29 JP JP2016166921A patent/JP6291540B2/ja not_active Expired - Fee Related
-
2017
- 2017-06-28 US US15/636,460 patent/US20170298118A1/en not_active Abandoned
-
2018
- 2018-02-09 JP JP2018021637A patent/JP6505882B2/ja not_active Expired - Fee Related
-
2019
- 2019-03-27 JP JP2019060059A patent/JP6813928B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| JP2018076386A (ja) | 2018-05-17 |
| US20170298118A1 (en) | 2017-10-19 |
| JP2013521498A (ja) | 2013-06-10 |
| CN102858798A (zh) | 2013-01-02 |
| HK1180345A1 (zh) | 2013-10-18 |
| WO2011109308A1 (en) | 2011-09-09 |
| DK2542576T3 (en) | 2016-08-01 |
| JP5998261B2 (ja) | 2016-09-28 |
| JP6813928B2 (ja) | 2021-01-13 |
| JP5797210B2 (ja) | 2015-10-21 |
| US9725500B2 (en) | 2017-08-08 |
| JP2019167339A (ja) | 2019-10-03 |
| JP2016216502A (ja) | 2016-12-22 |
| JP6291540B2 (ja) | 2018-03-14 |
| EP2542576A4 (en) | 2013-09-04 |
| CN102858798B (zh) | 2015-06-17 |
| JP2015227891A (ja) | 2015-12-17 |
| CA2788289C (en) | 2018-08-21 |
| CA2788289A1 (en) | 2011-09-09 |
| ES2581314T3 (es) | 2016-09-05 |
| EP2542576A1 (en) | 2013-01-09 |
| US20120322686A1 (en) | 2012-12-20 |
| JP6505882B2 (ja) | 2019-04-24 |
| PT2542576T (pt) | 2016-07-14 |
| EP2542576B1 (en) | 2016-04-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT2542576T (pt) | Métodos para rastreio de anticorpos | |
| ZA201209004B (en) | Anti-fgfr2 antibodies | |
| GB201000467D0 (en) | Antibodies | |
| IL221371A0 (en) | Anti-lrp6 antibodies | |
| IL249501A0 (en) | A process for creating antibodies | |
| IL220404A (en) | Antiseptic antibodies | |
| GB201103955D0 (en) | Antibodies | |
| GB201112056D0 (en) | Antibodies | |
| LT2536764T (lt) | Anti-cd28 humanizuoti antikūnai | |
| PL2603528T3 (pl) | Przeciwciała Fab-glikozylowane | |
| GB201020738D0 (en) | Antibodies | |
| ZA201302459B (en) | Antibodies | |
| IL222533A0 (en) | Methods for detecting antibodies | |
| EP2558587A4 (en) | METHOD FOR DISPLAYING ANTIBODIES | |
| GB201002238D0 (en) | Antibodies | |
| PL2558499T3 (pl) | Przeciwciała anty-VLA-4 | |
| GB201120317D0 (en) | Screening method | |
| EP2714074A4 (en) | ANTIBODIES AGAINST EMR1 | |
| GB201013373D0 (en) | Screening apparatus | |
| GB201015416D0 (en) | Screening method | |
| GB201006496D0 (en) | Screening method | |
| GB201015419D0 (en) | Screening method | |
| GB201005062D0 (en) | Antibodies | |
| GB201020751D0 (en) | Antibodies | |
| GB201105572D0 (en) | Screening method-III |